Hims & Hers Health stock is down, with reports citing various reasons including an fda decision on a peptide and a missed sales expectation. However, there are conflicting reports about the fda's action, with some indicating a negative decision and one suggesting a positive outcome. The stock's overall performance has been declining over the past six months.